Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

被引:31
|
作者
McClung, M. R. [1 ]
Balske, A. [2 ]
Burgio, D. E. [3 ]
Wenderoth, D. [4 ]
Recker, R. R. [5 ]
机构
[1] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Procter & Gamble Co, Mason, OH USA
[4] Warner Chilcott Deutschland GmbH, Weiterstadt, Germany
[5] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
关键词
Bone mineral density; Delayed-release; Enteric-coated; Histomorphometry; Osteoporosis; Risedronate; Weekly; LONG-TERM RISEDRONATE; NONVERTEBRAL FRACTURES; BISPHOSPHONATE THERAPY; VERTEBRAL FRACTURES; BONE QUALITY; WOMEN; ALENDRONATE; EFFICACY; ARCHITECTURE; RISK;
D O I
10.1007/s00198-012-2175-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance. This 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years. Women with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated. A total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated. Risedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.
引用
收藏
页码:301 / 310
页数:10
相关论文
共 50 条
  • [41] The effectiveness of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis
    Yildirim, K
    Güreser, G
    Karatay, S
    Senel, K
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S121 - S121
  • [42] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    McClung, M. R.
    Zanchetta, J. R.
    Racewicz, A.
    Roux, C.
    Benhamou, C. -L.
    Man, Z.
    Eusebio, R. A.
    Beary, J. F.
    Burgio, D. E.
    Matzkin, E.
    Boonen, S.
    Delmas, P.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 293 - 299
  • [43] Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
    M. R. McClung
    J. R. Zanchetta
    A. Racewicz
    C. Roux
    C.-L. Benhamou
    Z. Man
    R. A. Eusebio
    J. F. Beary
    D. E. Burgio
    E. Matzkin
    S. Boonen
    P. Delmas
    Osteoporosis International, 2013, 24 : 293 - 299
  • [44] Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis
    Luckey, M
    Kagan, R
    Greenspan, S
    Bone, H
    Kiel, RDP
    Simon, J
    Sackarowitz, J
    Palmisano, J
    Chen, E
    Petruschke, RA
    de Papp, AE
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2004, 11 (04): : 405 - 415
  • [45] Risedronate pharmacokinetics following daily (5 mg/day) and weekly (35 and 50 mg/week) oral dosing regimens to postmenopausal women.
    Burgio, D
    Russell, D
    Desliva, B
    Namour, F
    Thompson, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P32 - P32
  • [46] The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
    Brown, JP
    Kendler, DL
    McClung, MR
    Emkey, RD
    Adachi, JD
    Bolognese, MA
    Li, Z
    Balske, A
    Lindsay, R
    CALCIFIED TISSUE INTERNATIONAL, 2002, 71 (02) : 103 - 111
  • [47] The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis
    J.P. Brown
    D.L. Kendler
    M.R. McClung
    R.D. Emkey
    J.D. Adachi
    M.A. Bolognese
    Z. Li
    A. Balske
    R. Lindsay
    Calcified Tissue International, 2002, 71 : 103 - 111
  • [48] Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis
    Yildirim, K
    Gureser, G
    Karatay, S
    Melikoglu, MA
    Ugur, M
    Erdal, A
    Senel, K
    Billen, H
    JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION, 2005, 18 (3-4) : 85 - 89
  • [49] The effectiveness of alendronate (70 mg weekly) in women with postmenopausal osteoporosis
    Martchenkova, L. A.
    Dreval, A. V.
    Kryukova, I. V.
    Tishenina, R. S.
    Milov, N. M.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S44 - S44
  • [50] Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
    Kukulka, Michael
    Eisenberg, Corey
    Nudurupati, Sai
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2011, 4 : 213 - 220